Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation
2008-003540-11Phase 3Active
- Sponsor
- HOVON
- Start
- Nov 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of cyclosporine, mycophenolate mofetil and cyclophosphamide in graft-versus-host disease (GVHD) (2 arms), sponsored by HOVON. Primary endpoint: Proportion of patients with non-severe GVHD within 180 days after randomization. Started Nov 2009; status: active.
02
Drugs
cyclosporinemycophenolate mofetilcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2008-003540-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003540-11.